allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
Mixed Phenotype Acute Leukemia
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
71 Active assets in the Mixed Phenotype Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin St. Jude Children's Research Hospital | Phase 4 | BB |
Cytosin-Arabinosid Children's Oncology Group | Phase 4 | BB |
DEXAMETHASONE St. Jude Children's Research Hospital | Phase 4 | BB |
METHOTREXATE Children's Oncology Group | Phase 4 | BB |
ETOPOSIDE Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →